1.Clinical epidemiology of gastric cancer.
Tiing Leong ANG ; Kwong Ming FOCK
Singapore medical journal 2014;55(12):621-628
Gastric cancer is the second leading cause of cancer-related mortality and the fourth most common cancer globally. There are, however, distinct differences in incidence rates in different geographic regions. While the incidence rate of gastric cancer has been falling, that of gastric cardia cancers is reportedly on the rise in some regions. Helicobacter pylori (H. pylori) infection is a major risk factor of non-cardia gastric cancer, and data has emerged concerning the role of H. pylori eradication for primary prevention of gastric cancer. Dietary, lifestyle and metabolic factors have also been implicated. Although addressing these other factors may contribute to health, the actual impact in terms of cancer prevention is unclear. Once irreversible histological changes have occurred, endoscopic surveillance would be necessary. A molecular classification system offers hope for molecularly tailored, personalised therapies for gastric cancer, which may improve the prognosis for patients.
Female
;
Global Health
;
Helicobacter Infections
;
complications
;
prevention & control
;
Helicobacter pylori
;
Humans
;
Incidence
;
Male
;
Obesity
;
complications
;
Risk Factors
;
Stomach Neoplasms
;
epidemiology
;
genetics
;
microbiology
;
prevention & control
2.Roadmap for elimination of gastric cancer in Korea.
The Korean Journal of Internal Medicine 2015;30(2):133-139
Most gastric cancers are caused by infection with the common human bacterial pathogen, Helicobacter pylori. It is now accepted that gastric cancer can be prevented and virtually eliminated by H. pylori eradication and this knowledge was responsible for country-wide H. pylori eradication combined with secondary cancer prevention for those with residual risk that was introduced in Japan in 2013. Korea is a high H. pylori prevalence and high gastric cancer incidence country and a good candidate for a gastric cancer elimination program. The presence of an H. pylori infection is now considered as an indication for treatment of the infection. However, antimicrobial drug resistance is common among H. pylori in Korea making effective therapy problematic. Country-wide studies of the local and regional antimicrobial resistance patterns are needed to choose the most appropriate therapies. H. pylori and gastric cancer eradication can be both efficient and cost effective making it possible and practical to make Korea H. pylori and gastric cancer free. There is no reason to delay.
Anti-Bacterial Agents/*therapeutic use
;
Disease Eradication
;
Drug Resistance, Bacterial
;
Helicobacter Infections/*drug therapy/epidemiology/microbiology
;
Helicobacter pylori/*drug effects/growth & development
;
Humans
;
Prevalence
;
Primary Prevention/*methods
;
Republic of Korea/epidemiology
;
Risk Assessment
;
Risk Factors
;
Stomach Neoplasms/epidemiology/microbiology/*prevention & control
;
Treatment Outcome
3.The Effect of Aspirin Alone or Aspirin Plus Additional Antiplatelets Therapy on Upper Gastrointestinal Hemorrhage.
Suh Eun BAE ; Seong Eun KIM ; Sung Ae JUNG ; So Yoon YOON ; Ki Nam SHIM ; Hye Kyung JUNG ; Tae Hun KIM ; Kwon YOO ; Il Hwan MOON
The Korean Journal of Gastroenterology 2011;57(4):213-220
BACKGROUND/AIMS: The increasing incidence of cardiovascular disease has led to an increase in the frequency of upper gastrointestinal (GI) hemorrhage due to the use of antiplatelet agents. This study examined the clinical characteristics of patients with upper GI hemorrhage who were administered aspirin alone or a combination treatment of antiplatelet agents. METHODS: A 656 patients who underwent drug-eluting coronary stenting at Ewha Mokdong Hospital in 2008 were divided into three groups according to the antiplatetlet agents used after the intervention; groups of aspirin alone, aspirin plus clopidogrel, and aspirin, and clopidogrel plus another antiplatelet agent, respectively. Patients admitted with GI hemorrhage in the same period without a medication history of antiplatelet or nonsteroidal anti-inflammatory drugs were used as the control hemorrhage group. The medical records were reviewed. RESULTS: Significant GI symptoms were observed in 21.1% of total patients, of whom 48.2% had ulcers. The upper GI hemorrhage rate was 3.8%. There was no significant difference in the hemorrhage rate between three groups. Compared to the control hemorrhage group, the endoscopic variables of the antiplatelet-related hemorrhage group were not significantly different. However, the Helicobacter pylori infection rate was lower, the admission period was longer, and the mortality rate was higher in the antiplatelet-related hemorrhage group (p<0.05, respectively). There was no direct association between restarting or discontinuance of antiplatelets after the hemorrhage event and mortality. CONCLUSIONS: Adding other antiplatelet agents to aspirin did not increase the hemorrhage rate. However, active diagnostic and therapeutic efforts are recommended in patients with GI symptoms during antiplatelet therapy.
Aged
;
Aspirin/*adverse effects/therapeutic use
;
Cardiovascular Diseases/prevention & control
;
Drug Therapy, Combination
;
Drug-Eluting Stents
;
Endoscopy, Gastrointestinal
;
Female
;
Gastrointestinal Hemorrhage/*chemically induced/mortality/prevention & control
;
Helicobacter Infections/complications/epidemiology
;
Helicobacter pylori
;
Humans
;
Male
;
Middle Aged
;
Peptic Ulcer/complications/epidemiology
;
Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
;
Retrospective Studies
;
Risk Factors
;
Ticlopidine/adverse effects/analogs & derivatives/therapeutic use
4.Helicobacter pylori Eradication for Prevention of Metachronous Recurrence after Endoscopic Resection of Early Gastric Cancer.
Chang Seok BANG ; Gwang Ho BAIK ; In Soo SHIN ; Jin Bong KIM ; Ki Tae SUK ; Jai Hoon YOON ; Yeon Soo KIM ; Dong Joon KIM
Journal of Korean Medical Science 2015;30(6):749-756
Controversies persist regarding the effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer (EGC). The aim of this study was to assess the efficacy of Helicobacter pylori eradication after endoscopic resection of EGC for the prevention of metachronous gastric cancer. A systematic literature review and meta-analysis were conducted using the core databases PubMed, EMBASE, and the Cochrane Library. The rates of development of metachronous gastric cancer between the Helicobacter pylori eradication group vs. the non-eradication group were extracted and analyzed using risk ratios (RRs). A random effect model was applied. The methodological quality of the enrolled studies was assessed by the Risk of Bias table and by the Newcastle-Ottawa Scale. Publication bias was evaluated through the funnel plot with trim and fill method, Egger's test, and by the rank correlation test. Ten studies (2 randomized and 8 non-randomized/5,914 patients with EGC or dysplasia) were identified and analyzed. Overall, the Helicobacter pylori eradication group showed a RR of 0.467 (95% CI: 0.362-0.602, P < 0.001) for the development of metachronous gastric cancer after endoscopic resection of EGC. Subgroup analyses showed consistent results. Publication bias was not detected. Helicobacter pylori eradication after endoscopic resection of EGC reduces the occurrence of metachronous gastric cancer.
Adult
;
Aged
;
Aged, 80 and over
;
Combined Modality Therapy/statistics & numerical data
;
Comorbidity
;
Female
;
Gastroscopy/*statistics & numerical data
;
Helicobacter Infections/epidemiology/*prevention & control
;
Humans
;
Incidence
;
Male
;
Middle Aged
;
Neoplasms, Second Primary/*epidemiology/pathology/*prevention & control
;
Risk Factors
;
Stomach Neoplasms/*epidemiology/pathology/*surgery
;
Treatment Outcome